pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

🤝 OmniAb’s Lilly pact: The California drug discovery shop has an ion channel collaboration and licensing agreement in place with the GLP-1 giant. Eli Lilly will pay up to $370 million ...

Aug 17, 2026·read at Endpoints ↗

August 17, 2026 10:36 AM EDT News Briefing Lil­ly to pay up to $370M for Om­niAb col­lab; Slate, Ful­crum forge re­verse merg­er Kyle LaHucik Biotech Correspondent 🤝 Om­niAb’s Lil­ly pact: The Cal­i­for­nia drug dis­cov­ery shop has an ion chan­nel col­lab­o­ra­tion and li­cens­ing agree­ment in place with the GLP-1 gi­ant. Eli Lil­ly … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
86 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY3ELI LILLY CO
topics
GLP-1 receptor2

related stories

  • Jun 10AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineBioPharma Dive
  • Jun 9Gilead and Merck’s latest trial success and flopSTAT
  • Jun 8STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trialsSTAT
  • Jun 8#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotEndpoints
  • Jun 8Major readouts from the annual diabetes conferenceSTAT